Active Ingredient History
Doconexent (Docosahexaenoic acid, DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina. DHA is widely used as a food supplement, and is beleived to support healthy brain development in young childred, prevent cardiovascular disease and cognitive decline during Alzheimer's disease. Most of these claims, however, were not supported by clinical trials. DHA spray is used as a tanner. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Accidents (Phase 4)
Affective Symptoms (Phase 3)
Anemia, Sickle Cell (Phase 3)
Anosmia (Phase 2)
Antisocial Personality Disorder (Phase 2/Phase 3)
Aortic Aneurysm, Abdominal (Phase 2)
Arterial Occlusive Diseases (Phase 2/Phase 3)
Asthenozoospermia (Phase 2/Phase 3)
Attention (Phase 3)
Autism Spectrum Disorder (Phase 4)
Autistic Disorder (Phase 4)
Bariatric Surgery (Early Phase 1)
beta-Thalassemia (Phase 2/Phase 3)
Biological Availability (Phase 4)
Blister (Early Phase 1)
Brain Concussion (Phase 2)
Brain Diseases (Phase 2/Phase 3)
Brain Injuries (Phase 4)
Brain Ischemia (Phase 4)
Breast Neoplasms (Phase 2)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Central Nervous System Diseases (Phase 2)
Chronic Pain (Phase 2)
Cognition Disorders (Phase 2)
Cognitive Dysfunction (Phase 3)
Colorectal Neoplasms (Phase 2)
Contact Lenses (Phase 4)
Corneal Diseases (Phase 4)
Coronary Disease (Phase 3)
COVID-19 (Phase 3)
Crohn Disease (Phase 4)
Cystic Fibrosis (Phase 2)
Dementia (Phase 2)
Depressive Disorder, Major (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2/Phase 3)
Diabetic Retinopathy (Phase 4)
Diaphragm (Phase 2)
Dietary Supplements (Phase 4)
Dry Eye Syndromes (Phase 4)
Exercise (Phase 3)
Fatty Liver (Phase 1/Phase 2)
Healthy Volunteers (Phase 3)
Heart Failure (Phase 1/Phase 2)
HIV (Phase 3)
HIV Infections (Phase 2)
Hypercholesterolemia (Phase 3)
Hyperlipidemias (Phase 4)
Hypertension, Pulmonary (Phase 2)
Hypertriglyceridemia (Phase 3)
Hypoglycemia (Phase 1/Phase 2)
Inflammation (Phase 4)
Intestinal Neoplasms (Phase 1/Phase 2)
Iron Overload (Phase 2/Phase 3)
Ischemic Stroke (Phase 4)
Learning Disabilities (Phase 4)
Liver Cirrhosis (Phase 1/Phase 2)
Liver Transplantation (Phase 2)
Lung Neoplasms (Phase 2)
Macular Edema (Phase 4)
Mastodynia (Phase 4)
Mental Disorders (Phase 2)
Metabolic Syndrome (Phase 1/Phase 2)
Mood Disorders (Phase 4)
Multiple Sclerosis, Relapsing-Remitting (Phase 2/Phase 3)
Myocardial Infarction (Phase 3)
Nervous System Diseases (Phase 4)
Neurocognitive Disorders (Phase 2)
Neurologic Manifestations (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 2)
Obesity (Phase 1/Phase 2)
Olfaction Disorders (Phase 2)
Organ Dysfunction Scores (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Oxidative Stress (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 1/Phase 2)
Pathologic Processes (Phase 2)
Peripheral Arterial Disease (Phase 2)
Pregnancy (Phase 3)
Primary Immunodeficiency Diseases (Phase 2/Phase 3)
Psoriasis (Phase 1)
Renal Insufficiency, Chronic (Phase 3)
Retinopathy of Prematurity (Phase 2)
Schizophrenia (Phase 2)
Sepsis (Phase 2)
Severe Acute Malnutrition (Phase 3)
Sjogren's Syndrome (Phase 2/Phase 3)
Stroke (Phase 4)
Urological Manifestations (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
